Pipeline2022-08-11T17:06:33+00:00

Publications

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

Lukas Kessler, Nader Hirmas, Kim M. Pabst, Rainer Hamacher, Justin Ferdinandus, Benedikt M. Schaarschmidt, Aleksandar Milosevic, Michael Nader, Lale Umutlu, Waldemar Uhl, Anke Reinacher-Schick, Celine Lugnier, David Witte, Marco Niedergethmann, Ken Herrmann, Wolfgang P. Fendler and Jens T. Siveke Abstract The fibroblast activation protein [...]

November 6th, 2023|Publications|

Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT

Weizhi Xu, Jiayu Cai, Tianxing Peng, Tinghua Meng, Yizhen Pang, Long Sun, Hua Wu, Jingjing Zhang, Xiaoyuan Chen and Haojun Chen Abstract Fibroblast activation protein is overexpressed in the stroma of several cancer types. 18F-fibroblast activation protein inhibitor (FAPI)–74 is a PET tracer with [...]

October 20th, 2023|Publications|

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study

Emil Novruzov1, Frederik L Giesel1,2, Yuriko Mori1, Peter L Choyke3, Mardjan Dabir1, Eduards Mamlins1, Dominik Schmitt1, Christina Antke1, Claudio Pinto4, Cristian Soza-Ried5,6, Rene Fernandez5, Horacio Amaral5,6, Vasko Kramer5,6, Leonardo Badinez7 Abstract Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT [...]

August 29th, 2023|Publications|

Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib

Meiqi Wu1, Yanyu Wang2, Qiao Yang1, Xuezhu Wang1, Xu Yang2, Haiqun Xing1, Xinting Sang2, Xiang Li3, Haitao Zhao2, Li Huo4 Abstract Fibroblast activation protein contributes to immunosuppression and resistance to immunotherapies. This study aimed to compare baseline 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT and 18F-FDG [...]

August 29th, 2023|Publications|

Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis

Alessio Rizzo1, Manuela Racca1, Federico Garrou2, Elisabetta Fenocchio3, Luca Pellegrino4, Domenico Albano5, Francesco Dondi5, Francesco Bertagna5, Salvatore Annunziata6, Giorgio Treglia7,8,9 Abstract Various papers have introduced the use of positron emission tomography (PET) with [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in different subtypes of gastric [...]

August 29th, 2023|Publications|

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

Yuriko Mori 1, Katharina Dendl 1, Jens Cardinale 1, Clemens Kratochwil 1, Frederik L Giesel # 1, Uwe Haberkorn # 1 Abstract Gallium 68 (68Ga)-labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is based on the molecular targeting of the FAP, which is known to be highly expressed in the major cell population in tumor stroma, termed [...]

February 5th, 2023|Publications|
Go to Top